Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: November 2013 (Specifically November 5-6, 2013)
Context: The filing reports a material corporate event regarding intellectual property rather than periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements.
Material Changes
Intellectual Property Grant: On November 5, 2013, the U.S. Patent and Trademark Office granted U.S. Patent No. 8,557,790 to Can-Fite Biopharma Ltd. and its subsidiary, OphthaliX Inc.
Patent Title: "A3 Adenosine receptor agonists for the reduction of intraocular pressure."
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future performance, or specific risk factors beyond the standard disclosure of the patent grant. The primary focus is the successful acquisition of the patent rights.
Investor Verification Checklist
- Verify the scope and validity of U.S. Patent No. 8,557,790 regarding A3 Adenosine receptor agonists.
- Confirm the commercialization status of the technology covered by the patent.
- Review the attached press release (Exhibit 99.1) for details on the patent's impact on the company's product pipeline.
- Check subsequent filings for any financial impact or licensing agreements related to this patent.